


# PIPELINE

 Login/Register to add a Project

 Download the PPT Slide

## CLINICAL DEVELOPMENT



# DISCOVERY PIPELINE

 Login/Register to add a Project

 Download the PPT Slide

HIT-TO-LEAD

LEAD-OPTIMIZATION

<b>Phenotypic Hit-to-Lead</b> University of Illinois, TB Alliance	<b>Combinatorial Biosynthetic Compounds</b> Shaw Environmental and University of Illinois at Chicago	<b>Nitroimidazoles</b> Nitroimidazoles TB Alliance, University of Auckland, University of Illinois	<b>Pyrazinamide Analogs</b> Pyrazinamide/nicotinamide analogs TB Alliance/Yonsei University
<b>M. tuberculosis Protein Kinase Inhibitors</b> Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles Vertex Pharmaceuticals, Incorporated	<b>Folate Biosynthesis Inhibitors</b> AstraZeneca, TB Alliance	<b>Diarylquinolines</b> Diarylquinoline TB Alliance, University of Auckland, Tibotec	<b>TL1 Inhibitors</b> Capuramycins Sequella
<b>Fungal metabolites</b> Mycosynthetix, University of Illinois at Chicago	<b>Phenotypic Hit-to-Lead</b> GlaxoSmithKline, TB Alliance	<b>Riminophenazines</b> Riminophenazines antibiotic TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois	<b>MTopo</b> Novel structural class AstraZeneca R and D Bangalore
<b>Actinomycete metabolites</b> University of Illinois at Chicago, Myongji University	<b>Malate Synthase Inhibitors</b> GlaxoSmithKline, Texas A&M University, TB Alliance	<b>InhA Inhibitors</b> Novel structural class GlaxoSmithKline, TB Alliance	<b>GyrB Inhibitors</b> AstraZeneca, TB Alliance
<b>DNA metabolism</b> Novel structural class AstraZeneca R and D Bangalore	<b>Menaquinone Synthase Inhibitors</b> Colorado State University, TB Alliance	<b>LeuRS inhibitors</b> Oxaboroles Anacor Pharmaceuticals	<b>SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis</b> Inorganic Compounds FAPESP/Brazil
<b>Phenotypic hit to lead</b> Multiple novel structural classes Lilly TB Drug Discovery Initiative	<b>Inhibitors of Mycobacterium Tuberculosis Energy Metabolism</b> Various Classes UPenn and TB Alliance	<b>Mycobacterial Gyrase Inhibitors</b> Novel structural class TB Alliance, GlaxoSmithKline	<b>Spectinomides</b> Spectinomycin analogs St Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix
<b>Novel hit-lead programs</b> Novel structural class Lilly TB Drug Discovery Initiative	<b>Inhibitors of isoprenoid biosynthesis</b> Lilly TB Drug Discovery Initiative		
<b>Phenotype Hit-to-Lead</b> Novel structural classes AstraZeneca R and D Bangalore	<b>Protein Splicing Inhibitors</b> Boston Biomedical Research Institute		